Update cookies preferences

Biologics papers

A. Kiricsi - Z. Bella - H. Kraxner - T. Szaloki - Z. Fent - B. Liktor - J. Huszka - P. Laszlo - D. Gobol - F. Helfferich - Z. Vaska - Z. Piski - L. Juhasz-Loisch - B. Horvath - G. Galantai - N. Krisztin - L. Toth - A. Bodi - M. Matuz - L. Lujber - A. Hirschberg

Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up

Rhinology 0-0: 0-0, 0000

J.J. Otten - R.J.L. van der Lans - L.B. Benoist - G.F.J.P.M. Adriaensen - R.D. Hoven - V. Verkest - W.J. Fokkens - S. Reitsma

Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP

Rhinology 0-0: 0-0, 0000

R. van der Lans - J.J. Otten - G.F.J.P.M. Adriaensen - L.B.L. Benoist - M.E. Cornet - D.R. Hoven - A.B. Rinia - W.J. Fokkens - S. Reitsma

Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps

Rhinology 62-3: 383-384, 2024

J. Mullol - V.J. Lund - M. Wagenmann - J.K. Han - A.N. Sousa - S.G. Smith - B. Mayer - R.H. Chan - W.J. Fokkens

Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE

Rhinology 62-3: 320-329, 2024

W.J. Fokkens - E. De Corso - V. Backer - M. Bernal-Sprekelsen - L. Bjermer - C. von Buchwald - A. Chaker - Z. Diamant - P. Gevaert - J. Han - C. Hopkins - V. Hox - L. Klimek - V.J. Lund - S. Lee - A. Luong - J. Mullol - A. Peters - O. Pfaar - S. Reitsma - S. Toppila-Salmi - G.K. Scadding - A.R. Sedaghat - A-S. Viskens - M. Wagenmann - P.W. Hellings

EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP

Rhinology 62-3: 287-298, 0000

P. Kemp - R.J.L. van der Lans - J.J. Otten - G.F.J.P.M. Adriaensen - L.B.L. Benoist - M.E. Cornet - D.R. Hoven - B. Rinia - V. Verkest - W.J. Fokkens - S. Reitsma

Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps

Rhinology 62-2: 202-207, 2024

F.F. Brkic - D.T. Liu - R. Klimbacher - N.J. Campion - T.J. Bartosik - E. Vyskocil - V. Stanek - A. Tu - T. Arnoldner - C. Bangert - K. Gangl - J. Eckl-Dorna - S. Schneider

Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD*

Rhinology 61-4: 320-327, 2023

S.E. Lee - N. Amin - L.P. Mannent - C. Bachert - G. Gross - S.H. Cho - A. Praestgaard - S. Siddiqui - S. Nash - S. Kamat - A.H. Khan - J.A. Jacob Nara

The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP

Rhinology 61-6: 531-540, 2023

H.H. Kariyawasam - D.P. Chandrasekharan - T. Jacques - P. Stokes - M. Dziadzio - S.B. Gane - D. Langan - J. Rimmer

Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis

Rhinology 61-2: 98-107, 2023

W.J. Fokkens - A-S. Viskens - V. Backer - D. Conti - E. De Corso - P. Gevaert - G.K. Scadding - M. Wagemann - M. Bernal-Sprekelsen - A. Chaker - E. Heffler - J.K. Han - E. Van Staeyen - C. Hopkins - J. Mullol - A. Peters - S. Reitsma - B.A. Senior - P.W. Hellings

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Rhinology 61-3: 194-202, 2023

R. Böscke - M. Heidemann - K-L. Bruchhage

Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data

Rhinology 61-3: 203-213, 2023

J.L. Boechat - B. Sousa-Pinto - L. Delgado - D. Silva

Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

Rhinology 61-3: 283-286, 2023

C. Hopkins - J.K. Han - V.J. Lund - C. Bachert - W.J. Fokkens - Z. Diamant - J. Mullol - A.R. Sousa - S.G. Smith - S. Yang - B. Mayer - S.W. Yancey - R.H. Chan - S.E. Lee

Evaluating treatment response to mepolizumab in patients with severe CRSwNP

Rhinology 61-2: 108-117, 2023

C. Bachert - P.W. Hellings - V.J. Lund - W.J. Fokkens - C. Hopkins - B. Mayer - R.H. Chan - S.G. Smith - A.R. Sousa - R. Alfonso-Cristancho - S. Yang - on behalf of the SYNAPSE Study Group

Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP

Rhinology 60-6: 474-478, 2022

B.R. Haxel - T. Hummel - K. Fruth - K. Lorenz - N. Gunder - P. Nahrath - M. Cuevas

Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps

Rhinology 60-6: 435-443, 2022

W.J. Fokkens

Unmet needs in biological treatment of CRS

Rhinology 60-3: 161-161, 2022

C. Hopkins

Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps

Rhinology 60-3: 162-168, 2022

T. Takeda - N. Yanagi - N. Fukasawa - E. Mori - M. Maeda - R. Sakaguchi - M. Tei - K. Omura - N. Otori

Respiratory epithelial adenomatoid hamartoma with nasal polyps affects dupilumab efficacy

Rhinology 60-2: 148-151, 2022

W.J. Fokkens - B.N. Landis - C. Hopkins - S. Reitsma - A.R. Sedaghat

Rhinology in review: from COVID-19 to biologicals

Rhinology 59-6: 490-500, 2021

S. Tsabouri - G. Ntritsos - F. Koskeridis - E. Evangelou - P. Olsson - K. Kostikas

Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis

Rhinology 59-6: 501-510, 2021

P.R.G. Eriksen - K.K. Jakobsen - K. Aanæs - V. Backer - C. von Buchwald

The potential role of biological treatment of chronic rhinosinusitis with nasal polyps: a nationwide cohort study

Rhinology 59-4: 374-379, 2021

M. Desrosiers - L.P. Mannent - N. Amin - G.W. Canonica - P.W. Hellings - P. Gevaert - J. Mullol - S.E. Lee - S. Fujieda - J.K. Han - C. Hopkins - W. Fokkens - R. Jankowski - S.H. Cho - X. Mao - M. Zhang - M.S. Rice - A.H. Khan - S. Kamat - N. Patel - N.M.H. Graham - M. Ruddy - C. Bachert

Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

Rhinology 59-3: 301-311, 2021

P.W. Hellings - E. Verhoeven - W.J. Fokkens

State-of-the-art overview on biological treatment for CRSwNP

Rhinology 59-2: 151-163, 2021

F. Kassem - R. Cohen-Confino - K. Meir-Shafrir - I. Lachover- Roth - A. Cohen-Engler - B. Nageris - Y. Rosman

Mepolizumab for eosinophilic chronic sinusitis with nasal polyposis: real-life experience

Rhinology 59-1: 110-112, 2021

Claus Bachert - S. James Zinreich - Peter W. Hellings - Joaquim Mullol - Daniel L. Hamilos - Philippe Gevaert - Robert M. Naclerio - Nikhil Amin - Vijay N. Joish - Chunpeng Fan - Donghui Zhang - Heribert Staudinger - Gianluca Pirozzi - Neil M.H. Graham - Asif Khan - Leda P. Mannent

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Rhinology 58-1: 10-17, 2020